Making sense of healthcare deals, technology, policy, and the occasional industry curveball.
Luba Greenwood and Ash Zenooz interview Jonathan Bush. Jonathan is the CEO of a16z-backed Zus Health, Executive Chairman of Firefly Health and a co-founder of Athena Health.
In this episode of Second Opinion, Christina Farr is joined by John Zutter, CEO of Lantern, and Matt Harmon, a long time benefits executive who's worked at fortune 100 companies to discuss the rising costs of healthcare, focusing on how large employers are addressing the financial impacts of tre
Let’s get real about the alliance between U.S. health care and employment
In this episode of Second Opinion, Christina Farr and Luba Greenwood chat with Mike Desjadon, CEO of Anomaly Health, about the state of American healthcare heading into 2025.
Plus, some thoughts about Transcarent buying Accolade!
How I’ve been thinking about recent events
Ash Zenooz and Luba Greenwood interview Andrea Ippolito about her extensive career in healthcare spanning academia, government, and the private sector, as well as her current role as founder and CEO of SimpiFed. They discuss the intricacies of government roles, the importance of women's health, and
Luba Greenwood and Ash Zenooz discuss the evolving biotech landscape, the impact of AI on drug discovery, the importance of using real-world evidence in drug development, and personal motivations for continuing efforts in the biotech field.
I teamed up with two health policy experts to explore the bull and bear case.
Christina Farr, Ash Zenooz, and Luba Greenwood are joined by Zeke Emanuel, a prominent oncologist, bioethicist, and influential voice in healthcare to discuss the impact of GLP-1 drugs, healthcare affordability, Trump's appointments, and AI in medicine. The second half of the episode was recorded a
Christina Farr and Ash Zenooz discuss the recent departures of prominent female CEOs from major healthcare companies and explore why progress in female leadership representation has been challenging in the healthcare industry.
That’s the question of the moment - and we explore it in-depth.
